Freya Biosciences closed a $38m series A financing last month and will be putting the cash towards the development of its vaginal microbial immunotherapeutic FB101, initially for the treatment of infertility.
Key Takeaways
- Freya Biosciences is developing FB101 and FB301, bacterial consortia aimed at altering infertile women’s vaginal flora
- Investors including Sofinnova Partners and OMX Ventures have contributed to Freya’s recent series A
“We estimate that about one-third of the population has [vaginal] dysbiosis – essentially the wrong type of bacteria,” Colleen Acosta, Freya’s CEO, told Scrip
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?